List of Excipients in Branded Drug AMAZON BASIC CARE NICOTINE POLACRILEX

Generic Drugs Containing AMAZON BASIC CARE NICOTINE POLACRILEX

Company	Ingredient	NDC	Excipient
Amazoncom Services LLC	nicotine polacrilex	72288-266	ASPARTAME
Amazoncom Services LLC	nicotine polacrilex	72288-266	CALCIUM POLYCARBOPHIL
Amazoncom Services LLC	nicotine polacrilex	72288-266	CORN SYRUP
Amazoncom Services LLC	nicotine polacrilex	72288-266	ICODEXTRIN
Amazoncom Services LLC	nicotine polacrilex	72288-266	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in AMAZON BASIC CARE NICOTINE POLACRILEX?

# Of NDCs	Excipient
2	ACESULFAME POTASSIUM
2	ASPARTAME
4	CALCIUM POLYCARBOPHIL
4	CORN SYRUP
4	ICODEXTRIN

Amazon Basic Care Nicotine Polacrilex: Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Amazon Basic Care nicotine polacrilex is an over-the-counter nicotine replacement therapy sold primarily as a private-label nicotine gum product. Its commercial position depends less on novel active-ingredient protection and more on low-cost excipient sourcing, chewing performance, taste masking, packaging, regulatory compliance, and retail distribution.

The product is generally positioned against branded nicotine gums such as Nicorette and other store-brand equivalents. The active ingredient, nicotine polacrilex, is regulated under the FDA’s OTC nicotine replacement framework. The commercial opportunity lies in improving patient acceptability and reducing manufacturing cost without changing the product’s monograph-compliant performance.

What is Amazon Basic Care nicotine polacrilex?

Amazon Basic Care nicotine polacrilex is nicotine gum containing nicotine polacrilex, an ion-exchange resin complex that releases nicotine during chewing. Common strengths are 2 mg and 4 mg nicotine per piece, corresponding to the standard OTC nicotine replacement strengths recognized by FDA regulation.[1]

Nicotine gum is a drug-delivery system rather than a conventional confectionery product. The user chews the gum intermittently and parks it between the cheek and gum. Nicotine is released through saliva and absorbed primarily through the oral mucosa. The formulation must balance:

• Nicotine release
• Gum texture and chew duration
• Flavor persistence
• Saliva stimulation
• Mouthfeel
• Storage stability
• Low irritation
• Manufacturing throughput

Amazon Basic Care products are typically private-label offerings. The brand owner, Amazon, may rely on a contract manufacturer or a licensed OTC drug manufacturer for formulation, production, packaging, and regulatory compliance. The specific manufacturer and excipient profile can vary by SKU, strength, flavor, manufacturing site, and market.

What excipients are used in nicotine polacrilex gum?

The exact inactive-ingredient list must be taken from the Drug Facts label and the applicable DailyMed or FDA listing for the specific Amazon Basic Care SKU. Nicotine gum products commonly use excipient classes that perform the following functions:

Excipient class	Typical function in nicotine gum	Commercial relevance
Gum base	Provides chew structure and controlled release	Major driver of texture and manufacturing behavior
Sweeteners	Improves palatability and masks nicotine bitterness	Supports adherence and flavor differentiation
Sugar alcohols	Provides bulk and sweetness, often with lower cariogenicity than sucrose	Affects cooling effect, laxation risk, and cost
Sodium carbonate or other alkalizing agents	Raises local pH and supports nicotine release from the resin complex	Affects release rate, irritation, and taste
Flavoring agents	Masks bitterness and provides consumer differentiation	Central to repeat purchase and adherence
Humectants	Retain moisture and reduce brittleness	Influences shelf life and chew quality
Waxes	Improves processing, coating, or surface appearance	Can affect gloss and packaging performance
Mineral fillers	Add bulk and modify hardness or chew	Affect density, compression, and mouthfeel
Film-forming agents	Support coatings or surface protection	Useful for moisture control and appearance
Lubricants and processing aids	Reduce sticking and improve manufacturing efficiency	Can reduce rejects and equipment downtime

Common nicotine gum excipients in the broader market include sorbitol, mannitol, sodium carbonate, magnesium oxide, calcium phosphate, glycerin, gum base, flavoring agents, acesulfame potassium, talc, carnauba wax, hypromellose, and cellulose-derived materials. The presence and concentration of any specific ingredient should not be assumed across all Amazon Basic Care products.

Why alkalizers matter

Nicotine polacrilex is an ionic complex. The formulation must support release of nicotine under the intended chewing conditions. Alkalizing agents can increase the proportion of nicotine available for mucosal absorption by raising local pH.

The formulation tradeoff is narrow. Excessive alkalinity can increase oral irritation and unpleasant taste. Insufficient alkalinity can reduce nicotine release and perceived efficacy. Excipient selection therefore has direct commercial consequences even when the active ingredient remains unchanged.

Why gum base is strategically important

Gum base is usually the highest-impact functional excipient in nicotine gum. Its composition controls:

• Initial hardness
• Chew resistance
• Elasticity
• Flavor release
• Nicotine-release profile
• Processing temperature
• Sticking to equipment
• Storage stability

A supplier that can provide a nicotine-gum base with consistent chew characteristics, low extractables, and reliable batch-to-batch performance may have more commercial value than a supplier offering a lower-cost sweetener alone.

How does FDA regulate nicotine polacrilex gum?

Nicotine replacement products are regulated as OTC drugs. FDA’s OTC monograph framework permits specified nicotine replacement products when they meet applicable conditions relating to active ingredients, dosage forms, labeling, directions, warnings, and quality requirements.[1]

For nicotine gum, the key regulatory controls include:

• Nicotine polacrilex strength
• Product labeling and directions
• Age-related warnings
• Smoking-cessation indication
• Use instructions, including the chew-and-park method
• Packaging and tamper considerations
• Stability and quality testing
• Manufacturing under current good manufacturing practice requirements

The product is not regulated like ordinary chewing gum. Excipient changes can require formal assessment of identity, strength, quality, purity, stability, release, microbial quality, and consumer safety.

What is the Orange Book status of Amazon Basic Care nicotine polacrilex?

Amazon Basic Care nicotine polacrilex is generally not dependent on a conventional new-drug patent estate or Orange Book exclusivity strategy. FDA’s Orange Book primarily organizes approved prescription drug products and certain other approved applications. OTC monograph products typically compete through compliance with the applicable monograph or other FDA authorization pathway rather than through a branded prescription-style exclusivity period.[2]

The commercial implications are significant:

• There is no conventional five-year new chemical entity exclusivity for nicotine polacrilex gum.
• Paragraph IV litigation is generally not the primary competitive mechanism.
• Product differentiation depends on price, distribution, flavor, quality, packaging, and brand visibility.
• A private-label manufacturer can compete without licensing a branded nicotine-gum patent portfolio, provided the product complies with FDA requirements and does not infringe enforceable third-party rights.

What patents protect nicotine gum formulations?

Patent exposure for nicotine gum can arise from several areas:

1. Nicotine-resin complexes and ion-exchange systems.
2. Gum-base composition.
3. Controlled-release structures.
4. Coated gum pieces.
5. Taste-masking systems.
6. Manufacturing processes.
7. Packaging that controls moisture or nicotine migration.
8. Combination products or specialized cessation regimens.

Older patents covering nicotine gum and nicotine polacrilex technology have existed, including patents associated with early nicotine replacement products. Many such patents have expired or become commercially less significant. The relevant question for Amazon Basic Care is not whether nicotine gum has ever been patented, but whether any unexpired claim covers the specific formulation, manufacturing process, or packaging used for the current product.

Publicly available product-label information does not establish that Amazon Basic Care relies on a proprietary, patent-protected excipient platform. Excipient ingredients such as sorbitol, glycerin, mannitol, sodium carbonate, and conventional gum-base materials are generally commodity or well-established pharmaceutical excipients. Patent risk is more likely to arise from combinations, process parameters, release profiles, or manufacturing know-how.

What excipient opportunities exist for Amazon Basic Care?

Low-cost reformulation

The largest near-term opportunity is cost reduction without perceptible loss of chew quality. Candidate strategies include:

• Dual-sourcing gum base
• Replacing high-cost flavor systems
• Optimizing sugar-alcohol ratios
• Reducing overage in volatile flavor components
• Improving powder flow and processing yield
• Lowering reject rates from sticking, cracking, or coating defects
• Using regional excipient suppliers with equivalent quality systems

A formulation change must preserve nicotine release, assay, content uniformity, stability, and consumer acceptability.

Flavor and irritation reduction

Nicotine gum has a recurring adherence problem: bitterness, throat irritation, mouth irritation, and an unpleasant aftertaste. Flavor-system improvements can create a stronger retail proposition than small active-ingredient changes.

Potential development areas include:

• Mint systems with longer flavor persistence
• Reduced bitterness through flavor modulation
• Lower-irritation alkalizer systems
• Cooling profiles that avoid excessive menthol intensity
• Flavor combinations designed for prolonged intermittent chewing
• Reduced post-chew bitterness

Flavor changes can be commercially valuable because nicotine replacement therapy is used repeatedly over weeks or months. A small improvement in tolerability may support persistence and repeat purchases.

Sugar-free and dental-positioning benefits

Nicotine gum is commonly formulated with sugar alcohols rather than sucrose. This supports a sugar-free positioning and can reduce concern about conventional sugar exposure. The formulation must still manage gastrointestinal tolerability, particularly where sorbitol or other polyols are used at meaningful quantities.

Commercial claims must remain consistent with FDA labeling requirements and applicable advertising rules. Dental positioning cannot substitute for formal substantiation.

Pediatric and accidental-exposure risk reduction

Nicotine is toxic in overdose. Excipient and packaging design can support risk reduction through:

• Child-resistant containers
• Unit-dose packaging
• Reduced nicotine migration
• Improved piece-count control
• More robust blister or pouch structures
• Better package instructions
• Moisture barriers that preserve product integrity

Packaging changes can have greater safety value than a minor excipient substitution. They also create opportunities for contract packagers and specialty packaging suppliers.

Which companies compete with Amazon Basic Care nicotine gum?

The competitive set includes branded nicotine replacement products, pharmacy and supermarket private labels, online retailers, and manufacturers supplying store-brand products. The principal branded benchmark is Nicorette, historically associated with Haleon. Other competition comes from nicotine lozenges, patches, nasal sprays, inhalers, and newer nicotine-delivery products.

Competitor category	Primary advantage	Excipient or formulation pressure
Branded nicotine gum	Recognition and established consumer trust	Requires strong flavor and chew performance
Store-brand gum	Lower price	Requires aggressive cost control
Nicotine lozenges	No chewing requirement	Competes on dissolution and taste
Nicotine patches	Simplified once-daily use	Competes on convenience, not flavor
Nicotine pouches	Discreet oral use	Creates pressure for low-irritation delivery
Online private labels	Distribution and search visibility	Requires reliable supply and reviews

Amazon’s potential advantage is digital merchandising, subscription purchasing, customer data, and private-label pricing. Its weakness is dependence on third-party manufacturing and the possibility of limited differentiation if the product is functionally equivalent to other store-brand nicotine gums.

What manufacturing and intellectual-property barriers affect the product?

The principal manufacturing barriers are technical rather than patent-based. Nicotine gum requires specialized processing equipment and controls for:

• Uniform distribution of nicotine polacrilex
• Gum-base mixing
• Temperature-sensitive flavor addition
• Piece weight and content uniformity
• Surface coating
• Moisture control
• Packaging integrity
• Stability over the labeled shelf life

Nicotine can migrate into packaging materials and may interact with adhesives, films, coatings, and elastomers. Packaging compatibility testing is therefore part of the product-development program.

Manufacturers also need experience with controlled handling of an active pharmaceutical ingredient that can produce occupational exposure concerns. A low-cost confectionery manufacturer is not automatically qualified to produce nicotine gum under pharmaceutical GMP requirements.

What generic launch risks exist for Amazon Basic Care nicotine gum?

Generic and private-label launch risk is moderate from a legal perspective but high from an execution perspective.

Legal risk

The product is exposed to:

• Monograph compliance disputes
• Labeling violations
• Manufacturing-quality findings
• Trademark or trade-dress claims
• Patent claims involving specialized formulations or processes
• Product-liability claims involving accidental ingestion or misuse

Paragraph IV risk is less central than in prescription products because the product does not depend on a conventional abbreviated new drug application and Orange Book patent certification framework.

Commercial risk

The more material risks are:

• Retail price compression
• Low product differentiation
• Negative reviews about taste or texture
• Supply interruptions
• Flavor or packaging obsolescence
• Consumer migration to nicotine pouches
• Reduced smoking prevalence
• Competition from lozenges and patches

A supplier that improves taste, chew duration, or package convenience can create a defensible commercial advantage even without a blocking patent.

How strong is the patent estate for Amazon Basic Care nicotine polacrilex?

The apparent patent strength is limited as a product-level differentiator. Nicotine polacrilex is an established active ingredient, and nicotine gum is a mature dosage form. The likely competitive moat is operational:

• Manufacturing qualification
• Consistent quality
• Supplier redundancy
• Retail placement
• Digital search ranking
• Price
• Consumer reviews
• Package design
• Regulatory execution

A stronger IP position could be developed around a genuinely differentiated release profile, reduced-irritation formulation, improved taste-masking system, or packaging technology. Any such strategy would require claim drafting around measurable formulation or performance parameters rather than a simple list of conventional excipients.

What licensing opportunities exist for nicotine gum excipients?

Licensing opportunities are most plausible in four areas:

1. Proprietary gum-base systems with improved chew and release.
2. Flavor-masking technologies that reduce nicotine bitterness.
3. Oral-mucosal irritation-reduction systems.
4. Moisture-barrier packaging and nicotine-retention systems.

An excipient supplier could pursue a formulation-development agreement with a contract manufacturer or private-label sponsor. The most commercially practical deal structure would likely combine technical transfer, supply rights, quality agreements, and volume-based pricing rather than a large royalty on a mature OTC product.

What is the commercial outlook for Amazon Basic Care nicotine polacrilex?

The product has a viable low-cost OTC position, but the category is mature and highly substitutable. Revenue exposure is therefore driven by category volume, Amazon’s private-label strategy, nicotine replacement demand, and the shift toward alternative nicotine products.

The strongest opportunities are:

• Better-tasting mint and fruit variants
• Lower-irritation formulations
• Unit-dose and travel packaging
• Multi-pack and subscription formats
• Cost-efficient dual sourcing
• Reformulation that improves chew consistency
• Packaging with stronger child-resistance controls
• Complementary product bundles with lozenges or patches

The weakest investment thesis is a conventional “new excipient” story with no measurable consumer or manufacturing benefit. In this category, excipient value must be demonstrated through lower cost, better tolerability, longer flavor duration, improved release, or reduced quality failures.

Key Takeaways

• Amazon Basic Care nicotine polacrilex is a mature OTC nicotine replacement product, generally sold as 2 mg or 4 mg nicotine gum.
• The active ingredient is established; excipient and manufacturing performance drive differentiation.
• Gum base, alkalizers, sweeteners, flavors, humectants, and packaging materials are the highest-value development areas.
• FDA monograph compliance is more important than conventional Orange Book exclusivity.
• Paragraph IV litigation is not the primary competitive risk.
• Patent opportunities are more likely in specialized formulations, release systems, manufacturing processes, and packaging than in standard excipients.
• The strongest commercial opportunities involve taste masking, irritation reduction, chew consistency, packaging safety, and supply-chain cost reduction.
• A private-label supplier’s defensibility is likely to come from execution, quality, distribution, and consumer acceptance rather than a broad foundational patent estate.

FAQs

Can Amazon Basic Care nicotine gum be reformulated with different sweeteners?

Yes, provided the revised formulation complies with applicable FDA requirements and maintains product quality, stability, nicotine release, labeling, and consumer safety. Sugar alcohol changes can affect taste, cooling sensation, texture, and gastrointestinal tolerability.

Does nicotine polacrilex require a novel drug application?

Not necessarily. OTC nicotine replacement products can be marketed under FDA’s applicable OTC regulatory framework when they meet the relevant conditions. The exact pathway depends on the product, labeling, formulation, and manufacturing status.[1]

Is nicotine gum protected by formulation patents?

Some nicotine-gum formulations and manufacturing methods have been patented. The practical risk depends on the claims, expiration status, jurisdiction, and the specific commercial formulation. Conventional excipients alone usually provide limited exclusivity.

Which excipient is most important for nicotine gum performance?

Gum base is usually the most important functional excipient because it affects chew, flavor release, nicotine release, processing, and storage. Alkalizers and flavor systems are also critical to perceived efficacy and adherence.

Can nicotine gum manufacturers use the same excipient system for 2 mg and 4 mg products?

They can use a common platform, but the nicotine-resin loading and active-to-excipient ratio may require separate process validation. Higher-strength products may produce different taste, irritation, release, and content-uniformity behavior.

References

1. U.S. Food and Drug Administration. (2022). Nicotine replacement therapy products: 21 C.F.R. Part 341. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2024). DailyMed: Current labeling for prescription and nonprescription drugs. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

5. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-210